Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 147

Similar articles for PubMed (Select 23354523)

1.

Assessing patterns of use of cardio-protective polypill component medicines in Australian women.

Stewart Williams JA, Wallick CJ, Byles JE, Doran CM.

Drugs Aging. 2013 Mar;30(3):193-203. doi: 10.1007/s40266-013-0051-6.

PMID:
23354523
2.

Predicting the impact of polypill use in a metabolic syndrome population: an effectiveness and cost-effectiveness analysis.

Zomer E, Owen A, Magliano DJ, Ademi Z, Reid CM, Liew D.

Am J Cardiovasc Drugs. 2013 Apr;13(2):121-8. doi: 10.1007/s40256-013-0019-2.

PMID:
23532687
3.

Could the polypill improve adherence? The patient perspective.

Bryant L, Martini N, Chan J, Chang L, Marmoush A, Robinson B, Yu K, Wong M.

J Prim Health Care. 2013 Mar 1;5(1):28-35.

PMID:
23457692
4.

A Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization.

Soliman EZ, Mendis S, Dissanayake WP, Somasundaram NP, Gunaratne PS, Jayasingne IK, Furberg CD.

Trials. 2011 Jan 5;12:3. doi: 10.1186/1745-6215-12-3.

5.

[The polypill: optimal strategy for reduction of cardiovascular disease].

Nathoe HM, Doevendans PA.

Ned Tijdschr Geneeskd. 2005 Jul 30;149(31):1740. Dutch.

PMID:
16114290
6.

Implementation of a simple age-based strategy in the prevention of cardiovascular disease: the Polypill approach.

Wald DS, Wald NJ.

J Eval Clin Pract. 2012 Jun;18(3):612-5. doi: 10.1111/j.1365-2753.2011.01637.x. Epub 2011 Jan 30.

PMID:
21276141
7.

Is a statin as part of a polypill the answer?

Robinson JG.

Curr Atheroscler Rep. 2009 Jan;11(1):15-22. Review.

PMID:
19080723
8.

The polypill to prevent cardiovascular disease: physicians' perspectives.

Viera AJ.

Curr Opin Cardiol. 2011 Sep;26(5):438-42. doi: 10.1097/HCO.0b013e3283496759. Review.

PMID:
21730826
9.

A 'polypill' aimed at preventing cardiovascular disease could prove highly cost-effective for use in Latin America.

Bautista LE, Vera-Cala LM, Ferrante D, Herrera VM, Miranda JJ, Pichardo R, Sánchez Abanto JR, Ferreccio C, Silva E, Oróstegui Arenas M, Chirinos JA, Medina-Lezama J, Pérez CM, Schapochnik N, Casas JP.

Health Aff (Millwood). 2013 Jan;32(1):155-64. doi: 10.1377/hlthaff.2011.0948.

PMID:
23297283
10.

Acceptance of a Polypill approach to prevent cardiovascular disease among a sample of U.S. physicians.

Viera AJ, Sheridan SL, Edwards T, Soliman EZ, Harris R, Furberg CD.

Prev Med. 2011 Jan;52(1):10-5. doi: 10.1016/j.ypmed.2010.09.016. Epub 2010 Oct 8.

11.

The causes and effects of socio-demographic exclusions from clinical trials.

Bartlett C, Doyal L, Ebrahim S, Davey P, Bachmann M, Egger M, Dieppe P.

Health Technol Assess. 2005 Oct;9(38):iii-iv, ix-x, 1-152. Review.

12.

Impact of age and sex on primary preventive treatment for cardiovascular disease in the West Midlands, UK: cross sectional study.

Sheppard JP, Singh S, Fletcher K, McManus RJ, Mant J.

BMJ. 2012 Jul 12;345:e4535. doi: 10.1136/bmj.e4535.

13.

Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey.

Yusuf S, Islam S, Chow CK, Rangarajan S, Dagenais G, Diaz R, Gupta R, Kelishadi R, Iqbal R, Avezum A, Kruger A, Kutty R, Lanas F, Lisheng L, Wei L, Lopez-Jaramillo P, Oguz A, Rahman O, Swidan H, Yusoff K, Zatonski W, Rosengren A, Teo KK; Prospective Urban Rural Epidemiology (PURE) Study Investigators.

Lancet. 2011 Oct 1;378(9798):1231-43. doi: 10.1016/S0140-6736(11)61215-4. Epub 2011 Aug 26.

PMID:
21872920
14.

[The polypill: not an effective strategy for reduction of cardiovascular disease].

Westerweel PE, van Wijk JP, Verhaar MC.

Ned Tijdschr Geneeskd. 2005 Jul 30;149(31):1741. Dutch.

PMID:
16114291
15.

An economic case for a cardiovascular polypill? A cost analysis of the Kanyini GAP trial.

Laba TL, Hayes A, Lo S, Peiris DP, Usherwood T, Hillis GS, Rafter N, Reid CM, Tonkin AM, Webster R, Neal BC, Cass A, Patel A, Rodgers A, Jan S.

Med J Aust. 2014 Dec 11;201(11):671-3.

PMID:
25495315
16.

Improving the cost-effectiveness of cardiovascular disease prevention in Australia: a modelling study.

Cobiac LJ, Magnus A, Barendregt JJ, Carter R, Vos T.

BMC Public Health. 2012 Jun 1;12:398. doi: 10.1186/1471-2458-12-398.

17.

Management of heart conditions in older rural and urban Australian women.

Jordan S, Wilson A, Dobson A.

Intern Med J. 2011 Oct;41(10):722-9. doi: 10.1111/j.1445-5994.2011.02536.x. Epub 2011 Jun 1.

PMID:
21627742
18.
19.

Effect of selected antihypertensives, antidiabetics, statins and diuretics on adjunctive medical treatment of glaucoma: a population based study.

Iskedjian M, Walker JH, Desjardins O, Robin AL, Covert DW, Bergamini MV, Einarson TR.

Curr Med Res Opin. 2009 Aug;25(8):1879-88. doi: 10.1185/03007990903035083.

PMID:
19530975
20.

Prospects and possible pitfalls of a preventive Polypill: confessions of a health promotion convert.

Green LW.

Eur J Clin Nutr. 2005 Aug;59 Suppl 1:S4-8; discussion S9.

PMID:
16052194
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk